scholarly journals The Effects of Treatment on Body Mass Index in Giant Cell Arteritis: A Post Hoc Analysis of the GiACTA Trial

2021 ◽  
Author(s):  
Naomi J. Patel ◽  
Xiaoqing Fu ◽  
Yuqing Zhang ◽  
Sebastian H. Unizony ◽  
Zachary S. Wallace ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Body Mass ◽  
Post Hoc Analysis ◽  
Post Hoc

scholarly journals FRI0687 Body mass index, smoking, socioeconomic status and the risk of giant cell arteritis

2017 ◽  
Author(s):  
K Jakobsson ◽  
LT Jacobsson ◽  
AJ Mohammad ◽  
KJ Warrington ◽  
EL Matteson ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Socioeconomic Status ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Body Mass

Body Mass Index Does Not Impact Clinical Efficacy of Ustekinumab in Crohn’s Disease: A Post Hoc Analysis of the IM-UNITI Trial

2020 ◽  
Author(s):  
Emily C L Wong ◽  
John K Marshall ◽  
Walter Reinisch ◽  
Neeraj Narula
Keyword(s):  
Body Mass Index ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Body Mass ◽  
Clinical Efficacy ◽  
Activity Index ◽  
Linear Trend ◽  
Post Hoc Analysis ◽  
Post Hoc ◽  
The Impact

Abstract Background This post hoc analysis aimed to evaluate the impact of BMI on the efficacy of ustekinumab in the IM-UNITI study. Methods The relationship between body mass index (BMI) and efficacy of ustekinumab was evaluated using data from a 44-week maintenance study of ustekinumab in Crohn’s disease (IM-UNITI, NCT01369355, YODA #2019–4105). The primary endpoints of interest were clinical remission (CR), defined as Crohn’s disease activity index <150 and corticosteroid-free CR at week 44. Patients were stratified into the following subgroups according to their BMI at study entry: underweight <18.5 kg/m2, normal 18.5 to 25 kg/m2, overweight 25 to <30 kg/m2, and obese ≥30 kg/m2. The χ 2 test of linear trend was conducted for comparisons of frequencies between the 3 cohorts. Multivariate regression analyses evaluated possible association between BMI and efficacy outcomes of CR and corticosteroid-free CR, with adjustment for variables found significant on univariate analyses. Results are presented as odds ratios with 95% confidence intervals. Data were analyzed using Stata/IC 15. Results A total of 254 patients treated with ustekinumab were included in this analysis. At week 44 of IM-UNITI, rates of CR did not differ among those whose BMI was underweight (67.9%%; 19 of 28 patients), normal (51.3%; 60 of 117), overweight (45.1%; 32 of 71), or obese (55.3%; 21 of 38; P = 0.89). Multivariate logistic analysis did not find BMI to be a significant predictor of CR when adjusted for covariates. Ustekinumab drug level at week 44 was significantly lower in obese patients (median level 2.98 mcg/mL; interquartile range [IQR], 2.86) compared with patients who were overweight (4.84 mcg/mL; IQR, 3.51; P = 0.021) or had underweight or normal BMI (4.43 mcg/m;, IQR, 2.82; P = 0.014). Conclusions Although BMI impacts ustekinumab drug levels, there was no impact of BMI on clinical efficacy. Further studies of the pharmacodynamic effects of ustekinumab in patients with high BMI are needed.

scholarly journals Body mass index and the risk of giant cell arteritis--results from a prospective study

Rheumatology ◽  
2014 ◽  
Vol 54 (3) ◽  
pp. 433-440 ◽  
Author(s):  
K. Jakobsson ◽  
L. Jacobsson ◽  
K. Warrington ◽  
E. L. Matteson ◽  
K. Liang ◽  
...  
Keyword(s):  
Body Mass Index ◽  
Prospective Study ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Body Mass ◽  
A Prospective Study

The Impact of a 12-Month Activity Tracker Intervention on Activity Behavior Across Body Mass Index Subgroups Among Recent Retirees: Post Hoc Analysis of a Randomized Controlled Trial

2021 ◽  
pp. 1-7
Author(s):  
Miika Tuominen ◽  
Kristin Suorsa ◽  
Jaana Pentti ◽  
Pasi Koski ◽  
Sari Stenholm ◽  
...  
Keyword(s):  
Physical Activity ◽  
Body Mass Index ◽  
Body Mass ◽  
Intervention Group ◽  
Intervention Effect ◽  
Post Hoc Analysis ◽  
Activity Tracker ◽  
Activity Behavior ◽  
Post Hoc ◽  
The Impact

Background: This study examined the effectiveness of a 12-month activity tracker-based intervention on activity behavior among recent retirees (Enhancing physical ACTivity and healthy aging among recent REtirees [REACT]) in subgroups based on body mass index. Methods: REACT trial randomized 231 participants (mean age 65.2) into intervention and control groups. Main outcomes were accelerometer-measured moderate-to-vigorous (MVPA) and light physical activity (LPA) and sedentary time (SED) measured at baseline and 3-, 6-, and 12-month follow-ups. As a post hoc analysis, the intervention effect was examined among participants with normal weight (n = 77), overweight (n = 89), and obesity (n = 61). Results: An intervention effect was observed among participants with obesity in LPA (time × group P = .045) mirrored by a similar, albeit nonsignificant, effect in SED (P = .067), but not in MVPA (P = .92). A transient increase of 41 minutes per day (95% confidence interval, 14 to 68) in LPA was observed at 6 months among the intervention group, with a concomitant decrease of 42 minutes per day (−72 to −12) in SED. However, these changes were not maintained at 12 months. No between-group differences in changes over time were observed among participants with normal or overweight. Conclusions: Activity trackers may be particularly suitable for promoting changes in LPA and SED among older adults with obesity. However, their long-term effectiveness might be limited.

Sign in / Sign up

Export Citation Format

Share Document